Aliases & Classifications for Ureter, Cancer of

MalaCards integrated aliases for Ureter, Cancer of:

Name: Ureter, Cancer of 57
Ureter Carcinoma 12 54 15 17 71
Malignant Neoplasm of Ureter 71 32
Ureteral Neoplasms 44 71
Ureter Cancer 12 15
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Ureteral Carcinoma 12
Ureteral Neoplasm 17

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant


HPO:

31
ureter, cancer of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11819 DOID:4939
OMIM® 57 191600
ICD9CM 34 189.2
MeSH 44 D014516
NCIt 50 C7543 C8993
SNOMED-CT 67 94121005
ICD10 32 C66
MedGen 41 C0153619
SNOMED-CT via HPO 68 126882009 263681008 363458004
UMLS 71 C0041955 C0153619 C0600079

Summaries for Ureter, Cancer of

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter, Cancer of, also known as ureter carcinoma, is related to ureter adenocarcinoma and transitional cell carcinoma. An important gene associated with Ureter, Cancer of is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Pathways in cancer and Platinum Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Pemetrexed and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include ureter, bone and endothelial, and related phenotypes are neoplasm of the ureter and cellular

More information from OMIM: 191600

Related Diseases for Ureter, Cancer of

Diseases related to Ureter, Cancer of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 ureter adenocarcinoma 31.8 KRT7 CEACAM5
2 transitional cell carcinoma 29.2 PLAUR PLAU MSH2 MLH1 KRT7 FGFR3
3 bladder cancer 28.7 TERT PLAUR PLAU NUMA1 MLH1 FGFR3
4 regional ureteric cancer 11.2
5 perforated corneal ulcer 10.3 PLAUR PLAU
6 intratubular embryonal carcinoma 10.3 PLAU KRT7
7 extrahepatic bile duct adenoma 10.3 MSH2 MLH1
8 autosomal dominant non-syndromic intellectual disability 8 10.3 MSH2 MLH1
9 appendix carcinoid tumor 10.3 MSH2 MLH1
10 mismatch repair cancer syndrome 10.3 MSH2 MLH1
11 cervical adenoma malignum 10.3 MSH2 KRT7
12 intracranial meningioma 10.3 MSH2 MLH1
13 in situ carcinoma 10.3
14 lower lip cancer 10.3 MSH2 MLH1
15 jejunal adenocarcinoma 10.3 MLH1 KRT7
16 colorectal cancer, hereditary nonpolyposis, type 6 10.3 MSH2 MLH1
17 colorectal cancer, hereditary nonpolyposis, type 5 10.3 MSH2 MLH1
18 ileum cancer 10.3 MSH2 KRT7
19 sebaceous gland neoplasm 10.3 MSH2 MLH1
20 sebaceous adenoma 10.3 MSH2 MLH1
21 small intestine adenocarcinoma 10.2 MSH2 MLH1
22 actinic cheilitis 10.2 MSH2 FGFR3
23 ureterolithiasis 10.2 ADRA1B ADRA1A
24 adenomyoma 10.2 MLH1 KRT7
25 melanocytic nevus syndrome, congenital 10.2 MSH2 MLH1
26 mixed fibrolamellar hepatocellular carcinoma 10.2 TERT KRT7
27 monophasic synovial sarcoma 10.2 MLH1 KRT7
28 dysplastic nevus syndrome 10.2 MSH2 MLH1
29 dacryocystocele 10.2 KRT7 FGFR3
30 granulosa cell tumor of the ovary 10.2 TERT KRT7
31 chronic inflammation of lacrimal passage 10.2 KRT7 FGFR3
32 leukoplakia of penis 10.2 KRT7 CEACAM5
33 urethral villous adenoma 10.2 KRT7 CEACAM5
34 mucinous adenofibroma 10.2 KRT7 CEACAM5
35 pancreatic foamy gland adenocarcinoma 10.1 KRT7 CEACAM5
36 malignant acrospiroma 10.1 KRT7 CEACAM5
37 anal paget's disease 10.1 KRT7 CEACAM5
38 pancreatic serous cystadenocarcinoma 10.1 KRT7 CEACAM5
39 urinary bladder villous adenoma 10.1 KRT7 CEACAM5
40 cutaneous mucoepidermoid carcinoma 10.1 KRT7 CEACAM5
41 external ear carcinoma 10.1 KRT7 CEACAM5
42 vulva adenocarcinoma 10.1 KRT7 CEACAM5
43 vulval paget's disease 10.1 KRT7 CEACAM5
44 nodular hidradenoma 10.1 KRT7 CEACAM5
45 hidradenoma 10.1 KRT7 CEACAM5
46 vaginal tubulovillous adenoma 10.1 KRT7 CEACAM5
47 female urethral cancer 10.1 KRT7 CEACAM5
48 eccrine adenocarcinoma 10.1 KRT7 CEACAM5
49 renal pelvis adenocarcinoma 10.1 KRT7 CEACAM5
50 bile duct cystadenocarcinoma 10.1 KRT7 CEACAM5

Comorbidity relations with Ureter, Cancer of via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Cancer
Deficiency Anemia Hydronephrosis
Prostatic Hypertrophy Renal Pelvis Carcinoma

Graphical network of the top 20 diseases related to Ureter, Cancer of:



Diseases related to Ureter, Cancer of

Symptoms & Phenotypes for Ureter, Cancer of

Human phenotypes related to Ureter, Cancer of:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 31 HP:0100516

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
G U:
cancer of ureter

Clinical features from OMIM®:

191600 (Updated 05-Mar-2021)

MGI Mouse Phenotypes related to Ureter, Cancer of:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.28 ADRA1B FGFR3 KRT7 MLH1 MSH2 NUMA1

Drugs & Therapeutics for Ureter, Cancer of

Drugs for Ureter, Cancer of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
3
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
4
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
6
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
7
Bevacizumab Approved, Investigational Phase 3 216974-75-3
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
10
Cobalamin Experimental Phase 3 13408-78-1 6857388
11 Hormones Phase 3
12 Micronutrients Phase 3
13 Trace Elements Phase 3
14 Vitamins Phase 3
15 Nutrients Phase 3
16 Gastrointestinal Agents Phase 3
17 Hematinics Phase 3
18 Vitamin B 12 Phase 3
19 Anti-Inflammatory Agents Phase 3
20 Hormone Antagonists Phase 3
21 Vitamin B12 Phase 3
22 glucocorticoids Phase 3
23 BB 1101 Phase 3
24 Antineoplastic Agents, Hormonal Phase 3
25 Antiemetics Phase 3
26 Albumin-Bound Paclitaxel Phase 3
27 Angiogenesis Inhibitors Phase 3
28 Immunoglobulin G Phase 3
29 Mitogens Phase 3
30 Antibodies, Monoclonal Phase 3
31 Immunoglobulins, Intravenous Phase 3
32 Endothelial Growth Factors Phase 3
33 Halichondrin B Phase 3
34
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
35
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
36
tannic acid Approved Phase 2 1401-55-4
37
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
38
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
39
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
40
Ifosfamide Approved Phase 2 3778-73-2 3690
41
Lonafarnib Approved, Investigational Phase 2 193275-84-2 148195
42
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
44
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
45
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
46
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
47
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
48
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
49
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
50
Denosumab Approved Phase 2 615258-40-7

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
2 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
3 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
4 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
5 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
6 Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle InvaSive and Locally Advanced Urothelial CaRcinoma (AMBASSADOR) Versus Observation Recruiting NCT03244384 Phase 3
7 An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Active, not recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
8 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
9 A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Not yet recruiting NCT04579224 Phase 3 Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
10 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
11 Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
12 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
13 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
14 A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
15 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder Completed NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
16 A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
17 A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis) Completed NCT00066352 Phase 2 bortezomib
18 Phase II Study Of Cisplatin, Gemcitabine, And ZD 1839 (IRESSA) (IND #61187; NSC 715055) For The Treatment Of Advanced Urothelial Tract Carcinoma Completed NCT00041106 Phase 2 gemcitabine hydrochloride;cisplatin;gefitinib
19 A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium Completed NCT00021099 Phase 2 ixabepilone
20 Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II Completed NCT00014144 Phase 2 gefitinib
21 A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00006376 Phase 2 chemotherapy;tipifarnib
22 A Phase II Study of Oxaliplatin in Urothelial Cancer Completed NCT00004203 Phase 2 oxaliplatin
23 A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract Completed NCT00003175 Phase 2 fluorouracil
24 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
25 A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
26 Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract Completed NCT01031420 Phase 2 single arm dose dense MVAC
27 A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy Completed NCT00749892 Phase 2 Erlotinib Hydrochloride
28 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
29 Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
30 A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
31 Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
32 A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
33 A Phase II Trial Of Adjuvant Chemotherapy For High Risk Transitional Cell Carcinoma Of The Urothelium Completed NCT00028860 Phase 2 carboplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
34 Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997 Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
35 Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer Completed NCT01031875 Phase 2 pazopanib hydrochloride
36 Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
37 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
38 Phase II Study of Genexol-PM, a Cremophor-free, Polymeric Micelle Formulation of Paclitaxel for Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
39 A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function. Completed NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
40 A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
41 Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
42 A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00310011 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
43 A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis) Completed NCT00112671 Phase 2 sorafenib tosylate
44 A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Completed NCT00101608 Phase 2 vinflunine
45 Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00066612 Phase 2 irinotecan hydrochloride
46 A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER Completed NCT00009867 Phase 2 arsenic trioxide
47 Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
48 Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
49 Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
50 Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00003105 Phase 1, Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide;paclitaxel

Search NIH Clinical Center for Ureter, Cancer of

Inferred drug relations via UMLS 71 / NDF-RT 51 :


pembrolizumab

Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter, Cancer of

Anatomical Context for Ureter, Cancer of

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter, Cancer of:

19
Ureter

MalaCards organs/tissues related to Ureter, Cancer of:

40
Bone, Endothelial, Kidney

Publications for Ureter, Cancer of

Articles related to Ureter, Cancer of:

(show all 32)
# Title Authors PMID Year
1
Familial occurrence of carcinoma of the ureter. 57
5923294 1966
2
[Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma]. 54 61
15191676 2004
3
[The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma]. 61 54
14981816 2004
4
[PRIMARY SMALL CELL NEUROENDOCRINE CARCINOMA OF THE URETER]. 61
30662049 2018
5
Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 27 cases. 61
29370814 2018
6
[Port-Site Metastasis of an Urothelial Carcinoma after Laparoscopic Nephroureterectomy : A Case Report]. 61
29103252 2017
7
[Concurrent renal cell carcinoma and urothelial carcinoma: long-term follow-up study of 24 cases]. 61
28355757 2017
8
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review. 61
27765044 2016
9
The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients. 61
27029078 2016
10
Comprehensive data analysis of human ureter proteome. 61
26937461 2016
11
[Port-Site Metastasis of Urothelial Carcinoma after Laparoscopic Nephroureterectomy: A Case Report]. 61
27018412 2016
12
A proteomic glimpse into human ureter proteome. 61
26442468 2016
13
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. 61
25474136 2014
14
Pulmonary tumor thrombotic microangiopathy induced by ureteral carcinoma: a necropsy case report. 61
25298767 2014
15
The impact of real-time 3d imaging by ultra-high speed optical coherence tomography in urothelial carcinoma. 61
24289823 2013
16
Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. 61
18379418 2008
17
In-depth proteomic profiling of the normal human kidney glomerulus using two-dimensional protein prefractionation in combination with liquid chromatography-tandem mass spectrometry. 61
17711322 2007
18
[Ureter cancer of complete double renal pelvis and ureter: a case report]. 61
12613013 2002
19
Triplicity of the malignant tumor of the urinary bladder. 61
8711348 1994
20
[Urothelial cancer of the upper urinary tract]. 61
8372411 1993
21
In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity. 61
8483327 1993
22
[A study on cathepsin B-like substance in patients with urological cancer]. 61
8464189 1993
23
[Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ]. 61
1481770 1992
24
Comparison of radiation sensitivity for three cell lines as measured by the cloning assay and the micro-nucleus test. 61
2260014 1990
25
Analysis of cell survival after multiple fractions per day and low-dose-rate irradiation of two in vitro cultured rat tumor cell lines. 61
4048393 1985
26
[Phase II study of cis-diamminedichloroplatinum (II) in genitourinary cancer]. 61
6764107 1982
27
[An organ-preserving operation in primary ureteral cancer]. 61
7210928 1980
28
Thermal enhancement of the effectiveness of gamma radiation for induction of reproductive death in cultured mammalian cells. 61
309451 1978
29
Comparison of three mammalian cell-lines with respect to their sensitivities to hyperthermia, gamma-rays and U.V.-radiation. 61
301514 1977
30
[Papillary ureter carcinoma as a recurrence of renal pelvis tumor after nephrectomy; diagnosis and therapy]. 61
13399291 1956
31
[Primary ureter carcinoma]. 61
14380939 1955
32
[Case report of a metastatic ureter carcinoma]. 61
14397652 1955

Variations for Ureter, Cancer of

Expression for Ureter, Cancer of

Search GEO for disease gene expression data for Ureter, Cancer of.

Pathways for Ureter, Cancer of

Pathways related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.28 TERT MSH2 MLH1 FGFR3
2 10.62 MSH2 MLH1
3 10.32 ADRA1B ADRA1A
4 9.74 PLAUR PLAU

GO Terms for Ureter, Cancer of

Cellular components related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MSH2 MLH1

Biological processes related to Ureter, Cancer of according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 9.63 FGFR3 ADRA1B ADRA1A
2 regulation of cardiac muscle contraction GO:0055117 9.54 ADRA1B ADRA1A
3 regulation of vasoconstriction GO:0019229 9.52 ADRA1B ADRA1A
4 fibrinolysis GO:0042730 9.51 PLAUR PLAU
5 regulation of muscle contraction GO:0006937 9.49 ADRA1B ADRA1A
6 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.48 ADRA1B ADRA1A
7 isotype switching GO:0045190 9.43 MSH2 MLH1
8 somatic hypermutation of immunoglobulin genes GO:0016446 9.4 MSH2 MLH1
9 adrenergic receptor signaling pathway GO:0071875 9.37 ADRA1B ADRA1A
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.32 MSH2 MLH1
11 positive regulation of isotype switching to IgA isotypes GO:0048298 9.26 MSH2 MLH1
12 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MSH2 MLH1
13 positive regulation of heart rate by epinephrine-norepinephrine GO:0001996 8.96 ADRA1B ADRA1A
14 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MSH2 MLH1

Molecular functions related to Ureter, Cancer of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatched DNA binding GO:0030983 9.26 MSH2 MLH1
2 adrenergic receptor activity GO:0004935 9.16 ADRA1B ADRA1A
3 guanine/thymine mispair binding GO:0032137 8.96 MSH2 MLH1
4 alpha1-adrenergic receptor activity GO:0004937 8.62 ADRA1B ADRA1A

Sources for Ureter, Cancer of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....